Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

Markets & Finance

Brean Murray Cuts Encysive Pharma to Hold


Brean Murray downgraded Encysive Pharmaceuticals (ENCY

to hold from accumulate, citing the Food and Drug Administration's recent request for more clinical trial work researching the drug Thelin.

Analyst Jonathan Aschoff says the development was almost entirely unexpected by the Street. He believes it will send the company's shares down sharply Monday. Barring significant ambrisentan delays, he no longer believes Thelin will have any meaningful lead time to the market over its competitor ambrisentan. He says the companies will have to fight it out for market share on relatively equal ground.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus